A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
NCT01445119 is a phase 1 interventional trial sponsored by Eli Lilly and Company. As of 21 Nov 2026, it is completed. It studies Carboplatin and Enzastaurin in Recurrent Gliomas. The registry lists an enrollment of 58 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2007 and a primary completion date of 31 Jul 2013.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01445119 |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Eli Lilly and Company |
| Enrollment | 58 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Recurrent Gliomas |
| Drugs | Carboplatin and Enzastaurin |
| Start | 31 Jan 2007 |
| Primary completion | 31 Jul 2013 |
| Study completion | 31 Jul 2013 |
| Last update posted | 28 Aug 2013 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joohee Sul, M.D.
National Cancer Institute (NCI)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01445119
Each answer restates registry values shown on this page.
What is NCT01445119?
NCT01445119 is a phase 1 interventional trial sponsored by Eli Lilly and Company. It studies Carboplatin and Enzastaurin in Recurrent Gliomas.
Who leads NCT01445119?
The registry names Joohee Sul, M.D. (principal investigator, National Cancer Institute (NCI)) as the overall official.
Where does NCT01445119 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01445119 study?
The registered drug and biological interventions are Carboplatin and Enzastaurin.
When did NCT01445119 end?
The registry lists a primary completion date of 31 Jul 2013 and a study completion date of 31 Jul 2013. The sponsor last updated the record on 28 Aug 2013.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.